Janney Montgomery Scott LLC Raises Stock Position in DaVita Inc. (NYSE:DVA)

Janney Montgomery Scott LLC boosted its stake in DaVita Inc. (NYSE:DVA - Free Report) by 16.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,591 shares of the company's stock after purchasing an additional 3,468 shares during the period. Janney Montgomery Scott LLC's holdings in DaVita were worth $4,031,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DVA. Blue Trust Inc. raised its holdings in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company's stock valued at $29,000 after buying an additional 78 shares during the last quarter. Family Firm Inc. purchased a new stake in shares of DaVita during the second quarter worth about $43,000. Versant Capital Management Inc grew its stake in shares of DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company's stock worth $45,000 after purchasing an additional 155 shares during the last quarter. Friedenthal Financial purchased a new position in DaVita during the 2nd quarter valued at about $48,000. Finally, Point72 Hong Kong Ltd purchased a new stake in DaVita in the 2nd quarter worth approximately $68,000. Institutional investors own 90.12% of the company's stock.

DaVita Stock Performance

Shares of DVA stock traded down $0.71 during trading hours on Friday, reaching $149.66. The company had a trading volume of 748,662 shares, compared to its average volume of 859,702. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The business has a fifty day moving average price of $157.15 and a 200-day moving average price of $146.80. DaVita Inc. has a one year low of $82.79 and a one year high of $168.50. The firm has a market cap of $12.27 billion, a PE ratio of 16.14, a price-to-earnings-growth ratio of 0.84 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to analysts' expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm's revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.85 EPS. Sell-side analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In other news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares in the company, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Javier Rodriguez sold 50,000 shares of the firm's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares in the company, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 173,482 shares of company stock valued at $27,387,069. Insiders own 2.00% of the company's stock.

Wall Street Analyst Weigh In

DVA has been the subject of a number of recent analyst reports. Bank of America upped their target price on DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a report on Wednesday, August 7th. Truist Financial boosted their price target on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research report on Monday, October 7th. TD Cowen raised their price objective on DaVita from $139.00 to $150.00 and gave the company a "hold" rating in a research report on Wednesday, July 24th. UBS Group increased their price objective on shares of DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research report on Thursday, August 8th. Finally, Barclays lifted their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.